Company focus: immunotherapy specialist BioNTech

24 April 2020

Like many companies announcing projects targeting COVID-19, German immunotherapeutics specialist BioNTech (Nasdaq: BNTX) experienced a share price fillip when it announced plans for a vaccine in March.

But the company’s mRNA vaccine program, which will see the company join forces with New York-based pharma giant Pfizer (NYSE: PFE), is just one part of what makes the firm interesting for analysts and investors alike.

Before it finally went public at the end of 2019, the Mainz-headquartered company was Europe’s largest privately-held biotech firm, raising in excess of $1.1 billion from private funds.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK